We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Remicade® Crohn's Disease Registry Across Canada (Study P02793) (RemiTRAC®)

This study has been terminated.
(Satisfied a post-marketing commitment to Canadian Health Authorities.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00755937
First Posted: September 19, 2008
Last Update Posted: June 22, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
  Purpose
This registry is a multi-center, prospective, observational program that will gather and analyze data on subjects with Crohn's disease being treated with Remicade® as per approved product monograph in Canada. In contrast to a controlled clinical trial, there is no imposed experimental intervention and treatment with Remicade® is determined solely by the subject's physicians. Thus, the data captured and reported in this registry will reflect a "real world" approach to the treatment of Crohn's disease with Remicade®.

Condition Intervention
Crohn's Disease Other: Data collection post infusion

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Remicade® Treatment Registry Across Canada in Crohn's Disease

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Clinical Response at 12 Months (Decrease in Crohn's Disease Activity Index [CDAI]>= 70 Points AND >= 25% From Baseline). [ Time Frame: 12 months after baseline ]
    CDAI is calculated based on 8 factors: # of liquid stools, abdominal pain, patient well-being, Crohn's complications, need for anti-diarrheal medications, abdominal mass, hematocrit, and weight. CDAI can range from 0 to 600. Remission is < 150, and moderate to severe disease ranges from 220 to 450.

  • Clinical Response at 24 Months (Decrease in CDAI >= 70 Points AND >= 25% From Baseline). [ Time Frame: 24 months after baseline ]
    CDAI is calculated based on 8 factors: # of liquid stools, abdominal pain, patient well-being, Crohn's complications, need for anti-diarrheal medications, abdominal mass, hematocrit, and weight. CDAI can range from 0 to 600. Remission is < 150, and moderate to severe disease ranges from 220 to 450.

  • Clinical Response at 36 Months (Decrease in CDAI >= 70 Points AND >= 25% From Baseline). [ Time Frame: 36 months after baseline ]
    CDAI is calculated based on 8 factors: # of liquid stools, abdominal pain, patient well-being, Crohn's complications, need for anti-diarrheal medications, abdominal mass, hematocrit, and weight. CDAI can range from 0 to 600. Remission is < 150, and moderate to severe disease ranges from 220 to 450.

  • Clinical Remission at 12 Months (CDAI <= 150 Points). [ Time Frame: 12 months after baseline ]
    CDAI is calculated based on 8 factors: # of liquid stools, abdominal pain, patient well-being, Crohn's complications, need for anti-diarrheal medications, abdominal mass, hematocrit, and weight. CDAI can range from 0 to 600. Remission is < 150, and moderate to severe disease ranges from 220 to 450.

  • Clinical Remission at 24 Months (CDAI <= 150 Points). [ Time Frame: 24 months after baseline ]
    CDAI is calculated based on 8 factors: # of liquid stools, abdominal pain, patient well-being, Crohn's complications, need for anti-diarrheal medications, abdominal mass, hematocrit, and weight. CDAI can range from 0 to 600. Remission is < 150, and moderate to severe disease ranges from 220 to 450.

  • Clinical Remission at 36 Months (CDAI <= 150 Points). [ Time Frame: 36 months after baseline ]
    CDAI is calculated based on 8 factors: # of liquid stools, abdominal pain, patient well-being, Crohn's complications, need for anti-diarrheal medications, abdominal mass, hematocrit, and weight. CDAI can range from 0 to 600. Remission is < 150, and moderate to severe disease ranges from 220 to 450.


Secondary Outcome Measures:
  • Number of Serious Adverse Events [ Time Frame: Throughout study (up to 36 months) ]

Enrollment: 556
Study Start Date: February 2002
Study Completion Date: September 2007
Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Subjects receiving Remicade
Crohn's disease subjects receiving Remicade® per Product Monograph.
Other: Data collection post infusion

Detailed Description:
Subjects will be selected for this registry using a non-probability sampling method.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primarily from community centers and some academic centers.
Criteria

Inclusion Criteria:

  • Patient was given the Patient Information Brochure; AND,
  • Patient has never been treated with Remicade® (patient is naïve to Remicade® at the time of registration); AND,
  • Patient is a good candidate to receive Remicade® as per the product monograph; AND,
  • Patient has agreed to complete the Patient Diary for one week prior to each visit in the registry; AND,
  • Patient has signed the approved consent form.

Exclusion Criteria:

  • Per product monograph
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00755937     History of Changes
Other Study ID Numbers: P02793
First Submitted: August 26, 2008
First Posted: September 19, 2008
Results First Submitted: September 29, 2008
Results First Posted: June 11, 2009
Last Update Posted: June 22, 2015
Last Verified: May 2015

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Infliximab
Dermatologic Agents
Gastrointestinal Agents
Antirheumatic Agents